Systemic Lupus Erythematosus (SLE) is a chronic, systemic inflammatory autoimmune disease in which the body’s immune system mistakenly attacks various tissues, causing widespread damage throughout the body with devastating symptoms ranging from severe fatigue, joint pain and swelling, skin rashes, arthritis, photosensitivity (or sensitivity to sunlight), fever, anemia, life-threatening kidney involvement, neurological symptoms and hematologic disorders.
J&J’s approach to SLE
Challenges remain in the disease management of SLE, and there is a great need to develop new approved treatments with proven safety profiles.
Building on our legacy of leadership in immunology innovation, we are currently evaluating an immunoselective treatment, designed to potentially address the underlying cause of the disease without impacting other immune functions. This investigational therapy is being studied across multiple auto- and alloantibody-driven diseases, including SLE.
